IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
IO Biotech (Nasdaq: IOBT) showcased its scientific leadership at the 2025 AACR Annual Meeting through an educational session on cancer vaccines. The company's scientific co-founder, Dr. Mads Hald Andersen, chaired and presented at the session, focusing on immune-modulatory vaccines (IMVs).
Dr. Andersen's presentation highlighted the dual mechanism of action of IO102-IO103, IO Biotech's most advanced therapeutic cancer vaccine. The vaccine targets both tumor cells and host immune suppressive cells by activating T cells against IDO+ and PDL1+ cells. Recent data suggests it can reprogram the tumor microenvironment (TME) through inflammatory cytokine induction and macrophage phenotypic changes, promoting a more immune-permissive environment.
IO Biotech (Nasdaq: IOBT) ha dimostrato la sua leadership scientifica al Meeting Annuale AACR 2025 con una sessione educativa sui vaccini contro il cancro. Il cofondatore scientifico dell'azienda, Dr. Mads Hald Andersen, ha presieduto e presentato la sessione, concentrandosi sui vaccini immuno-modulatori (IMV).
La presentazione del Dr. Andersen ha evidenziato il duplice meccanismo d'azione di IO102-IO103, il vaccino terapeutico contro il cancro più avanzato di IO Biotech. Il vaccino agisce sia contro le cellule tumorali sia contro le cellule immunosoppressive dell'ospite, attivando le cellule T contro le cellule IDO+ e PDL1+. Dati recenti suggeriscono che possa riprogrammare il microambiente tumorale (TME) attraverso l'induzione di citochine infiammatorie e modifiche fenotipiche dei macrofagi, favorendo un ambiente più permissivo al sistema immunitario.
IO Biotech (Nasdaq: IOBT) demostró su liderazgo científico en la Reunión Anual AACR 2025 mediante una sesión educativa sobre vacunas contra el cáncer. El cofundador científico de la empresa, Dr. Mads Hald Andersen, presidió y presentó la sesión, enfocándose en vacunas inmunomoduladoras (IMVs).
La presentación del Dr. Andersen destacó el doble mecanismo de acción de IO102-IO103, la vacuna terapéutica contra el cáncer más avanzada de IO Biotech. La vacuna apunta tanto a las células tumorales como a las células inmunosupresoras del huésped, activando células T contra células IDO+ y PDL1+. Datos recientes sugieren que puede reprogramar el microambiente tumoral (TME) mediante la inducción de citocinas inflamatorias y cambios fenotípicos en macrófagos, promoviendo un ambiente más permisivo para el sistema inmunológico.
IO Biotech (나스닥: IOBT)는 2025년 AACR 연례회의에서 암 백신에 관한 교육 세션을 통해 과학적 리더십을 선보였습니다. 회사의 과학 공동창립자인 Dr. Mads Hald Andersen가 세션을 주재하고 발표했으며, 면역 조절 백신(IMV)에 중점을 두었습니다.
Andersen 박사의 발표는 IO Biotech의 가장 진보된 치료용 암 백신인 IO102-IO103의 이중 작용 기전을 강조했습니다. 이 백신은 종양 세포와 숙주의 면역 억제 세포 모두를 표적으로 하여 IDO+ 및 PDL1+ 세포에 대해 T 세포를 활성화합니다. 최근 데이터는 염증성 사이토카인 유도와 대식세포 표현형 변화를 통해 종양 미세환경(TME)을 재프로그램하여 면역 허용 환경을 조성할 수 있음을 시사합니다.
IO Biotech (Nasdaq : IOBT) a démontré son leadership scientifique lors de la réunion annuelle AACR 2025 à travers une session éducative sur les vaccins contre le cancer. Le cofondateur scientifique de l'entreprise, Dr. Mads Hald Andersen, a présidé et présenté la session, en se concentrant sur les vaccins immunomodulateurs (IMV).
La présentation du Dr Andersen a mis en lumière le double mécanisme d'action de IO102-IO103, le vaccin thérapeutique anticancéreux le plus avancé d'IO Biotech. Le vaccin cible à la fois les cellules tumorales et les cellules immunosuppressives de l'hôte en activant les lymphocytes T contre les cellules IDO+ et PDL1+. Des données récentes suggèrent qu'il peut reprogrammer le microenvironnement tumoral (TME) via l'induction de cytokines inflammatoires et des modifications phénotypiques des macrophages, favorisant un environnement plus permissif pour le système immunitaire.
IO Biotech (Nasdaq: IOBT) präsentierte seine wissenschaftliche Führungsrolle auf dem AACR Jahrestreffen 2025 durch eine Bildungssitzung über Krebsimpfstoffe. Der wissenschaftliche Mitbegründer des Unternehmens, Dr. Mads Hald Andersen, leitete und präsentierte die Sitzung mit Fokus auf immunmodulatorische Impfstoffe (IMVs).
Dr. Andersens Vortrag hob den dualen Wirkmechanismus von IO102-IO103 hervor, dem fortschrittlichsten therapeutischen Krebsimpfstoff von IO Biotech. Der Impfstoff richtet sich sowohl gegen Tumorzellen als auch gegen immunsuppressive Wirtszellen, indem er T-Zellen gegen IDO+ und PDL1+ Zellen aktiviert. Neuere Daten deuten darauf hin, dass er das Tumormikroumfeld (TME) durch Induktion entzündlicher Zytokine und phänotypische Veränderungen von Makrophagen umprogrammieren kann, was ein immunfreundlicheres Umfeld fördert.
- Scientific leadership demonstrated in cancer vaccine development
- Advanced dual-mechanism therapeutic vaccine showing promising mechanism of action
- Novel approach to reprogramming tumor microenvironment demonstrated
- None.
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The session brought together leading oncology scientists and explored the latest advancements in cancer vaccine research, from preclinical innovation to clinical implementation, providing perspective on the future of cancer vaccines and their potential to reshape cancer immunotherapy (session #ED59).
The session included presentations of key developments in RNA-based, dendritic cell and immune-modulatory vaccines. Dr. Andersen delivered the presentation on IMVs, a new class of therapeutic cancer vaccines that reshape the tumor microenvironment (TME). His talk highlighted the dual mechanism of action of the most clinically advanced immune modulatory therapeutic cancer vaccine, IO102-IO103 (developed by IO Biotech), which targets both tumor cells and the host immune suppressive cells by stimulating activation and expansion of T cells against IDO+ and PDL1+ cells. He also shared recent data showing that this approach may reprogram the TME through induction of inflammatory cytokines and phenotypic changes in macrophages, supporting a more immune-permissive environment.
“Dr. Andersen's scientific vision laid the foundation for IO Biotech’s approach to immune-modulatory vaccines, and his contributions continue to shape how we think about treating cancer,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “We’re proud to have him as a co-founder, and deeply grateful for the way he continues to share his insights with the broader scientific community. His work helps push the entire field forward.”
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead investigational cancer vaccine candidate, Cylembio® (imsapepimut and etimupepimut, adjuvanted) also known as IO102-IO103 in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Cylembio® is a registered trademark of IO Biotech ApS, a subsidiary of IO Biotech.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
julie.funesti@edelman.com
FAQ
What was presented about IO Biotech's IO102-IO103 cancer vaccine at AACR 2025?
How does IO Biotech's (IOBT) cancer vaccine work to treat tumors?
What are the latest developments in IO Biotech's (IOBT) immune-modulatory vaccine research?
Who presented IO Biotech's cancer vaccine research at AACR 2025?
